Literature DB >> 25708605

Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?

Matthias Oelke1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25708605     DOI： 10.1007/s40261-014-0258-2

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


× No keyword cloud information.
  22 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Diagnosis and medical treatment of lower urinary tract symptoms in adult men: applying specialist guidelines in clinical practice.

Authors:  Matthias Oelke; Maximilian Burger; David Castro-Diaz; Emmanuel Chartier-Kastler; Miguel A Jimènez Cidre; Tom McNicholas; Piotr Radziszewski; Mike Kirby
Journal:  BJU Int       Date:  2011-12-07       Impact factor: 5.588

3.  Management of lower urinary tract symptoms in men: summary of NICE guidance.

Authors:  Clare Jones; Jennifer Hill; Christopher Chapple
Journal:  BMJ       Date:  2010-05-19

4.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

5.  Evaluative care guideline compliance is associated with provision of benign prostatic hyperplasia surgery.

Authors:  Seth A Strope; John T Wei; Alexandria Smith; Timothy J Wilt; Christopher S Saigal; Sean P Elliott
Journal:  Urology       Date:  2012-05-18       Impact factor: 2.649

6.  Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older.

Authors:  Matthias Oelke; Birgitt Wiese; Richard Berges
Journal:  World J Urol       Date:  2014-08-08       Impact factor: 4.226

7.  The cost of treating the 10 most prevalent diseases in men 50 years of age or older.

Authors:  Thomas C Fenter; Michael James Naslund; Manan B Shah; Michael T Eaddy; Libby Black
Journal:  Am J Manag Care       Date:  2006-03       Impact factor: 2.229

8.  Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment.

Authors:  E K Seaman; B Z Jacobs; J G Blaivas; S A Kaplan
Journal:  J Urol       Date:  1994-09       Impact factor: 7.450

Review 9.  A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.

Authors:  J C Nickel; S Sander; T D Moon
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

10.  Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.

Authors:  Steven T Bird; Joseph A C Delaney; James M Brophy; Mahyar Etminan; Sean C Skeldon; Abraham G Hartzema
Journal:  BMJ       Date:  2013-11-05
View more
  1 in total

1.  [Pharmacological treatment of benign prostatic hyperplasia].

Authors:  M Oelke; E Martinelli
Journal:  Urologe A       Date:  2016-01       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.